This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|July 26, 2017
Corning and Gerresheimer Collaborate on Valor Glass
Author(s)BioPharm International Editors
Corning and Gerresheimer have been working together to accelerate innovations for pharmaceutical glass packaging.
Advertisement
Valor Glass is a breakthrough glass container engineered for the storage and delivery of injectable drugs. Its strength, chemical durability, and damage resistance result in better protection for drug products. Valor Glass also enables increased throughput and higher levels of quality assurance for pharmaceutical companies.
Corning and Gerresheimer have been working together since 2015 to accelerate Corning innovations for the pharmaceutical glass packaging market.
“We are thrilled to be working with Corning on innovations to enhance quality across the industry. Valor Glass is a remarkable Type I glass with outstanding performance on every attribute,” said Uwe Röhrhoff, CEO of Gerresheimer AG, in a press release on July 24, 2017.
“Gerresheimer is a long-standing leader in the industry. They’ve been a terrific collaboration partner, and we’re excited to be working with them to bring Valor Glass to the pharmaceutical industry,” said Ron Verkleeren, vice-president and general manager, Corning Pharmaceutical Technologies, in the release.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5